Drug Approval | February 23, 2022
Zydus receives USFDA approval for Dapagliflozin tablets
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
To be marketed by Strides Pharma Inc. in the US market
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Resolv ER may remedy leading causes of blindness in adults
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Subscribe To Our Newsletter & Stay Updated
